ArticleJournal for immunotherapy of cancer2023
MDR1-EXPRESSING CD4
Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- MDR1 promotes CD8 T cell persistence in tumors and protects against cytotoxic chemotherapy.bioRxiv : the preprint server for biology · 2025Article
- The potential of antibody-drug conjugates in immunotherapy for non-small cell lung cancer: current progress and future.Frontiers in oncology · 2025Review
- Article
- Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.Journal for immunotherapy of cancer · 2024Article
- The ubiquitin-proteasome system in the tumor immune microenvironment: a key force in combination therapy.Frontiers in immunology · 2024Review
- Single-cell transcriptome reveals highly complement activated microglia cells in association with pediatric tuberculous meningitis.Frontiers in immunology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug resistance-1 (MDR1) transporter limits the intracellular accumulation of chemotherapies (paclitaxel, anthracyclines) used in breast cancer (BC) treatment. In addition to tumor cells, MDR1 is expressed on immune cell subsets in which it confers chemoresistance. Among human T cells, MDR1 is expressed by most CD8
methodsPhenotypic and functional characteristics of MDR1
resultsMDR1
conclusionMDR1 favored the enrichment of Th1.17 and Th17 in blood and tumor after NAC that correlated to clinical response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.